HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anna Bagnato Selected Research

ZD4054

8/2016Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.
10/2012The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
4/2011Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
6/2010Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
2/2009Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.
7/2007Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
7/2007ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
6/2006ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anna Bagnato Research Topics

Disease

60Neoplasms (Cancer)
04/2022 - 03/2002
32Ovarian Neoplasms (Ovarian Cancer)
04/2022 - 08/2002
29Carcinoma (Carcinomatosis)
04/2022 - 03/2002
16Neoplasm Metastasis (Metastasis)
04/2022 - 08/2002
10Hypoxia (Hypoxemia)
01/2020 - 08/2002
9Ovarian Epithelial Carcinoma
08/2016 - 06/2010
9Melanoma (Melanoma, Malignant)
04/2014 - 02/2004
7Carcinogenesis
01/2019 - 12/2005
3Multiple Myeloma
01/2020 - 01/2017
3Kaposi Sarcoma (Kaposi's Sarcoma)
08/2008 - 08/2003
3Uterine Cervical Neoplasms (Cancer of the Cervix)
11/2004 - 08/2002
2Breast Neoplasms (Breast Cancer)
04/2014 - 01/2013
2Brain Neoplasms (Brain Tumor)
08/2008 - 01/2008
2Endometrial Neoplasms (Endometrial Cancer)
08/2008 - 01/2008
2Ascites
06/2006 - 08/2002
2Prostatic Neoplasms (Prostate Cancer)
05/2004 - 02/2003
1Colorectal Neoplasms (Colorectal Cancer)
10/2017

Drug/Important Bio-Agent (IBA)

51Endothelin-1 (Endothelin 1)IBA
04/2022 - 03/2002
35Endothelin A ReceptorIBA
04/2022 - 11/2002
18Endothelins (Endothelin)IBA
03/2016 - 02/2003
15Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2016 - 08/2002
14Proteins (Proteins, Gene)FDA Link
01/2021 - 08/2002
13AtrasentanIBA
01/2007 - 08/2002
10macitentanIBA
04/2022 - 12/2014
10G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
01/2021 - 08/2008
9ArrestinIBA
01/2019 - 03/2014
8ZD4054IBA
08/2016 - 06/2006
8Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
04/2016 - 03/2002
7Endothelin Receptors (Endothelin Receptor)IBA
03/2013 - 08/2002
7Messenger RNA (mRNA)IBA
06/2006 - 08/2002
5Paclitaxel (Taxol)FDA LinkGeneric
06/2010 - 03/2002
4CateninsIBA
01/2019 - 10/2012
4Vascular Endothelial Growth Factor CIBA
04/2014 - 03/2009
4ErbB Receptors (EGF Receptor)IBA
10/2012 - 11/2004
4Endothelin B ReceptorIBA
06/2010 - 02/2004
4beta CateninIBA
02/2009 - 11/2004
4Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
02/2007 - 07/2004
4ProstaglandinsIBA
02/2007 - 07/2004
3Growth Factor ReceptorsIBA
01/2018 - 02/2007
3Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
03/2014 - 08/2002
3Mitogen-Activated Protein KinasesIBA
07/2007 - 11/2004
3Cadherins (E-Cadherin)IBA
01/2007 - 11/2004
3Peptide Hydrolases (Proteases)FDA Link
06/2006 - 08/2002
3Connexin 43 (Connexin43)IBA
11/2004 - 10/2003
3Peptides (Polypeptides)IBA
11/2004 - 03/2002
2Transcription Factors (Transcription Factor)IBA
01/2021 - 01/2019
2PlatinumIBA
11/2020 - 06/2010
2Pharmaceutical PreparationsIBA
01/2019 - 06/2010
2Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
11/2014 - 06/2010
2Small Interfering RNA (siRNA)IBA
04/2014 - 03/2009
2LectinsIBA
04/2014 - 01/2013
2Carrier Proteins (Binding Protein)IBA
04/2014 - 01/2013
2Conditioned Culture MediaIBA
04/2014 - 04/2014
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
03/2014 - 03/2013
2Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
03/2013 - 10/2012
2LigandsIBA
03/2013 - 11/2004
2Gefitinib (Iressa)FDA Link
10/2012 - 07/2007
2Matrix Metalloproteinases (MMPs)IBA
10/2012 - 11/2004
2beta-ArrestinsIBA
08/2010 - 02/2009
2integrin-linked kinaseIBA
08/2010 - 04/2006
2taxaneIBA
06/2010 - 05/2003
2Caspase 3 (Caspase-3)IBA
07/2007 - 06/2006
2Endothelin-3 (Endothelin 3)IBA
02/2007 - 11/2004
2epigallocatechin gallate (epigallocatechin-3-gallate)IBA
06/2006 - 06/2006
2TeaIBA
06/2006 - 06/2006
2PolyphenolsIBA
06/2006 - 06/2006
2Dinoprostone (PGE2)FDA Link
11/2004 - 11/2004
2A 192621IBA
11/2004 - 02/2004
2Cyclooxygenase 1IBA
11/2004 - 07/2004
2cyclo(Trp-Asp-Pro-Val-Leu)IBA
08/2002 - 03/2002
1ambrisentanFDA Link
01/2021
1NF-kappa B (NF-kB)IBA
01/2021
12-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA
01/2021
1CytokinesIBA
01/2020
1CortactinIBA
01/2019
1VinculinIBA
01/2019
1Actin Depolymerizing Factors (Cofilins)IBA
01/2018
1Rho Guanine Nucleotide Exchange FactorsIBA
01/2018
1Guanine Nucleotide Exchange Factors (Guanine Nucleotide Exchange Factor)IBA
01/2018
1GTP-Binding Proteins (G-Protein)IBA
01/2018
1Oxaliplatin (Eloxatin)FDA LinkGeneric
10/2017
1Fluorouracil (Carac)FDA LinkGeneric
10/2017
1GTP Phosphohydrolases (GTPases)IBA
08/2016
1Histones (Histone)IBA
04/2016
1p300-CBP-associated factorIBA
04/2016
1Biomarkers (Surrogate Marker)IBA
03/2016
1MicroRNAs (MicroRNA)IBA
01/2016
1ArrestinsIBA
01/2016
1AntibodiesIBA
04/2014
1Glycoproteins (Glycoprotein)IBA
04/2014
1Monoclonal AntibodiesIBA
04/2014
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
03/2014
1Biological ProductsIBA
09/2013
1Vascular Endothelial Growth Factor DIBA
03/2013
1Fibronectins (Fibronectin)IBA
01/2013
1matrigelIBA
10/2012
1Neutralizing AntibodiesIBA
10/2012

Therapy/Procedure

20Therapeutics
01/2021 - 03/2002
7Drug Therapy (Chemotherapy)
11/2020 - 12/2005
2Precision Medicine
01/2019 - 03/2016